Clinical Trials
27 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT07483684 2026-03-19
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07384377 2026-02-03
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03829462 2025-11-21
NEXT-REGIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Active not recruiting
NCT05425940 2025-10-23
STELLAR-303
Exelixis
Phase 3 Active not recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT05794971 2023-05-15
RIDER
Sun Yat-sen University
Phase 3 Recruiting
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT02664077 2022-04-14
ARGO
NSABP Foundation Inc
Phase 3 Terminated
NCT02773524 2022-01-13
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
Phase 3 Unknown
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT01774344 2020-08-20
RESORCE
Bayer
Phase 3 Completed
NCT02788279 2019-12-11
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Hoffmann-La Roche
Phase 3 Completed
NCT01853319 2019-04-22
REGARD
Bayer
Phase 3 Completed
NCT01939223 2017-10-20
COAST
Bayer
Phase 3 Terminated
NCT01584830 2016-02-08
CONCUR
Bayer
Phase 3 Completed
NCT01103323 2015-06-24
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Bayer
Phase 3 Completed
NCT01786538 2013-03-13
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Asan Medical Center
Phase 3 Withdrawn